Last reviewed · How we verify
Alamine (aluminium glycinate)
Alamine (generic name: aluminium glycinate) is a aluminium glycinate drug. It is currently in unknown development.
Alamine works by binding to aluminium ions, forming a complex that may help to mitigate aluminium toxicity.
Aluminium glycinate is a small molecule antacid. It is also known by the synonym ALUMINIUM GLYCINATE.
At a glance
| Generic name | aluminium glycinate |
|---|---|
| Drug class | aluminium glycinate |
| Therapeutic area | Metabolic |
| Phase | unknown |
Mechanism of action
Think of Alamine like a 'chaperone' that helps to keep aluminium ions from causing harm in the body. When aluminium ions are present, they can be toxic and cause problems. Alamine binds to these ions, forming a complex that is less likely to cause damage.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alamine CI brief — competitive landscape report
- Alamine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Alamine
What is Alamine?
How does Alamine work?
What is the generic name of Alamine?
What drug class is Alamine in?
What development phase is Alamine in?
Related
- Drug class: All aluminium glycinate drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing